We leverage both the expertise of our large Research & Development family and our unique network of external partners to research and develop the next generation of treatments against malaria. Further, we are working with clinical experts across the world to continuously study the efficacy and safety of our treatments, and exploring innovative ways to reduce malaria transmission.
Novartis currently leads two of the most advanced malaria development programs worldwide. KAF156, currently in phase 2, is the first compound from a novel class of antimalarials known as imidazolopiperazines. Available non-clinical and clinical data suggest KAF156 has the potential to be effective against infections resistant to all currently available antimalarial drugs. We are developing KAF156 with scientific and financial support from Medicines for Malaria Venture (in collaboration with the Bill & Melinda Gates Foundation), exploring ways to combine it with another agent to achieve a new treatment option for malaria.
The second compound, KAE609, also in phase 2, continues to be evaluated. In addition, our scientists are working on other projects, including a back-up compound to one of the two compounds currently in Phase 2 clinical development.